Hatch-Waxman 301

The Hatch-Waxman Act was enacted by Congress to encourage innovation in pharmaceutical research and development, and to shorten the time to market for generic drugs. Fish’s award-winning life sciences attorneys have developed a four-part webinar series to examine and explain the Act in detail. Earlier this year, Chad Shear and Terry Mahn presented the second program in the series, which discussed drug exclusivities, Orange Book strategies and citizen petitions as they relate to Hatch-Waxman litigation. Click here for replays of Hatch-Waxman 101 and Hatch-Waxman 201.

For the third installment in the series, Chad Shear and Terry Mahn led an in-depth discussion on:

• Labeling and induced infringement
• Use codes
• Patenting the label

This complimentary webinar is perfect for life sciences professionals interested in delving deeper into Hatch-Waxman topics, including litigation strategies.